2021
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy
Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Felip E, Rodríguez-Abreu D, Arance A, Boni V, Linette G, Schuchter L, Gonzalez-Cao M, Iannotti N, Ganti A, Hauke R, Berrocal A, Filbert E, Kluger H. 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Journal For ImmunoTherapy Of Cancer 2021, 9: a422-a422. DOI: 10.1136/jitc-2021-sitc2021.389.Peer-Reviewed Original ResearchAnti-PD-1 therapyMelanoma patientsMetastatic melanomaTumor PD-L1 expressionEffective anti-tumor immunityArm phase II trialCD40 agonist antibodyRefractory melanoma patientsRefractory metastatic melanomaAdvanced melanoma patientsPD-1 blockadePD-L1 expressionPhase II trialAnti-tumor immunitySubset of patientsOverall safety profileMajority of AEsOptimal therapeutic applicationReceptor binding profileInstitutional review boardClinical study teamNebraska Medical CenterOpen labelII trialTolerability profile
2014
The Greater Plains Collaborative: a PCORnet Clinical Research Data Network
Waitman L, Aaronson L, Nadkarni P, Connolly D, Campbell J. The Greater Plains Collaborative: a PCORnet Clinical Research Data Network. Journal Of The American Medical Informatics Association 2014, 21: 637-641. PMID: 24778202, PMCID: PMC4078294, DOI: 10.1136/amiajnl-2014-002756.Peer-Reviewed Original ResearchConceptsMedical CenterMercy HospitalTranslational Science Award initiativeChildren's Mercy HospitalTexas Southwestern Medical CenterHigh prevalence disordersMinnesota Academic Health CenterAmyotrophic lateral sclerosisKansas Medical CenterSouthwestern Medical CenterHealth Sciences CenterTexas Health Science CenterNebraska Medical CenterHealth centersBreast cancerLateral sclerosisRare diseaseAcademic health centersMarshfield ClinicMedical CollegeDiverse populationsSclerosisScience CenterClinicHospital
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply